2-((2S,5R,8S,11S)-5-Benzyl-11-(3-guanidinopropyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid

Catalog No. :
ACYZKK178
CAS No. :
137813-35-5
Molecular Formula :
C26H38N8O7
Molecular Weight :
574.64

IUPAC Name:2-((2S,5R,8S,11S)-5-benzyl-11-(3-guanidinopropyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid

2-((2S,5R,8S,11S)-5-Benzyl-11-(3-guanidinopropyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-((2S,5R,8S,11S)-5-Benzyl-11-(3-guanidinopropyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid
IUPAC Name2-((2S,5R,8S,11S)-5-benzyl-11-(3-guanidinopropyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid
Molecular FormulaC26H38N8O7
Molecular Weight574.64
SMILESCC(C)[C@@H]1NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC1=O
InChI KeyYYQUWEHEBOMRPH-NYUBLWNDSA-N
SynonymRGDFV PEPTIDE, CYCLIC;Cyclo(Arg-Gls-Asp-D-Phe-Val);EMD 66203, c(RGDfV);CYCLO(ARG-GLY-ASP-D-PHE-VAL);CYCLO(RGDD-FV);Cyclo(-Arg-Gly-Asp-D-Phe-Val) trifluoroacetate salt;Cyclo(Arg-Gly-Asp-D-Phe-Val) - CAS 137813-35-5 - Calbiochem;cRGDfV
CAS No.137813-35-5

Synthetic Route by SureRoute

1. ACYZKK178 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACYZKK178 route product structure diagram
    ACYZKK178137813-35-5
Inquiry

2. ACYZKK178 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACYZKK178 route product structure diagram
    ACYZKK178137813-35-5
Inquiry

Comments (0)